liftsiron
Owner/Admin
- Joined
- Nov 12, 2003
- Messages
- 19,026
Blood Donation May Not Reduce Risk of Testosterone-Induced Polycythemia
Benjamin Hull Chin-Yee, BSc, MA,
Alejandro Lazo-Langner, MD,
Terrie Foster, RN, BScN,
Cyrus C. Hsia, MD BSc, FRCPC,
Ian Chin-Yee, MD FRCPC
Crossmark: Check for Updates
Blood (2016) 128 (22): 5032.
https://doi.org/10.1182/blood.V128.22.5032.5032
Abstract
Background
olycythemia is the most common adverse effect of testosterone replacement therapy (TRT) and may predispose patients to adverse vascular events. Current Canadian guidelines recommend regular laboratory monitoring and discontinuing TRT or reducing the dose if the hematocrit exceeds 54% (hemoglobin ≥180 g/L). This threshold has been interpreted by some physicians and patients to indicate the need for phlebotomy or blood donation while on TRT.
Study Design and Methods: We reviewed all male blood donors in Southwestern Ontario at Canadian Blood Services from December 2013 to March 2016 who self-identified or were found on donor screening to be using TRT in any form. Hemoglobin concentration was measured at the time of donation or clinic visit and with each subsequent appointment in repeat donors.
Results:We report a case series of 39 patients on TRT who presented for blood donation over a two-year period. The mean hemoglobin at all donor clinic visits was 173 g/L (range 134-205 g/L, n = 108). Hemoglobin concentrations of ≥180 g/L (calculated hematocrit ≥54%) were measured at 25% of appointments. Of the 27 repeat donors, 12 (44%) had persistently elevated hemoglobin levels (≥180 g/L) at subsequent donations.
Conclusions: Hemoglobin concentrations were elevated in blood donors on TRT, with a significant number above levels recommended by current guidelines. These data also suggest that repeat blood donation was insufficient to maintain hematocrit below 54%. Our findings raise concerns about persistent risk of vascular events in these donors, particularly when coupled with the misperception by patients and health care providers that donation has abrogated the risks of TRT-induced polycythemia.
Disclosures
No relevant conflicts of interest to declare.
Topics:
blood donors, polycythemia, risk reduction, testosterone, hemoglobin, adverse effects, androgen replacement therapy, erythrocytosis, phlebotomy, hematocrit
Benjamin Hull Chin-Yee, BSc, MA,
Alejandro Lazo-Langner, MD,
Terrie Foster, RN, BScN,
Cyrus C. Hsia, MD BSc, FRCPC,
Ian Chin-Yee, MD FRCPC
Crossmark: Check for Updates
Blood (2016) 128 (22): 5032.
https://doi.org/10.1182/blood.V128.22.5032.5032
Abstract
Background
olycythemia is the most common adverse effect of testosterone replacement therapy (TRT) and may predispose patients to adverse vascular events. Current Canadian guidelines recommend regular laboratory monitoring and discontinuing TRT or reducing the dose if the hematocrit exceeds 54% (hemoglobin ≥180 g/L). This threshold has been interpreted by some physicians and patients to indicate the need for phlebotomy or blood donation while on TRT.Study Design and Methods: We reviewed all male blood donors in Southwestern Ontario at Canadian Blood Services from December 2013 to March 2016 who self-identified or were found on donor screening to be using TRT in any form. Hemoglobin concentration was measured at the time of donation or clinic visit and with each subsequent appointment in repeat donors.
Results:We report a case series of 39 patients on TRT who presented for blood donation over a two-year period. The mean hemoglobin at all donor clinic visits was 173 g/L (range 134-205 g/L, n = 108). Hemoglobin concentrations of ≥180 g/L (calculated hematocrit ≥54%) were measured at 25% of appointments. Of the 27 repeat donors, 12 (44%) had persistently elevated hemoglobin levels (≥180 g/L) at subsequent donations.
Conclusions: Hemoglobin concentrations were elevated in blood donors on TRT, with a significant number above levels recommended by current guidelines. These data also suggest that repeat blood donation was insufficient to maintain hematocrit below 54%. Our findings raise concerns about persistent risk of vascular events in these donors, particularly when coupled with the misperception by patients and health care providers that donation has abrogated the risks of TRT-induced polycythemia.
Disclosures
No relevant conflicts of interest to declare.
Topics:
blood donors, polycythemia, risk reduction, testosterone, hemoglobin, adverse effects, androgen replacement therapy, erythrocytosis, phlebotomy, hematocrit
